再発/難治性急性骨髄性白血病：洞察・疫学・市場予測 (～2034年)

当レポートでは、世界の主要7カ国における再発/難治性急性骨髄性白血病の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

• 米国
• 欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
• 日本

調査期間：2020年～2034年

レポートハイライト

• 再発/難治性急性骨髄性白血病の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
• 企業や研究機関は、再発/難治性急性骨髄性白血病の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
• 大手企業は再発/難治性急性骨髄性白血病の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
• 再発/難治性急性骨髄性白血病の新規治療薬の開発には、疾患病態のより深い理解が必要です。
• 当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

目次

第1章 重要な洞察

第2章 再発/難治性急性骨髄性白血病：エグゼクティブサマリー

第3章 再発/難治性急性骨髄性白血病：競合分析

第4章 再発/難治性急性骨髄性白血病：市場概要

• 総市場のシェア (％) の分布：2020年
• 総市場のシェア (％) の分布：2034年

第5章 再発/難治性急性骨髄性白血病：疾患の背景・概要

• 兆候と症状
• 病態生理
• リスク因子
• 診断

第6章 ペイシェントジャーニー

第7章 再発/難治性急性骨髄性白血病：疫学・患者人口

• 疫学：主要調査結果
• 前提・根拠：主要7カ国
• 疫学シナリオ：主要7カ国
  • 主要7カ国における再発/難治性急性骨髄性白血病の疫学シナリオ：2020-2034年
• 疫学：米国
• 疫学：欧州5カ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 疫学：日本

第8章 治療アルゴリズム・現在の治療薬・医療行為

• 再発/難治性急性骨髄性白血病の治療と管理
• 再発/難治性急性骨髄性白血病の治療アルゴリズム

第9章 アンメットニーズ

第10章 再発/難治性急性骨髄性白血病治療の主なエンドポイント

第11章 上市製品

• 主要7カ国の上市製品リスト
• 医薬品名・企業名
  • 製品説明
  • 規制のマイルストーン
  • その他の開発活動
  • 重要臨床試験
  • 主要臨床試験の概要

第12章 新興治療薬

• 主なクロスコンペティション
• 医薬品名・企業名
  • 製品説明
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
  • 製品プロファイル

第13章 再発/難治性急性骨髄性白血病：主要7カ国市場の分析

• 主要調査結果
• 主要7カ国の市場規模
• 主要7カ国の市場規模：治療薬別

第14章 属性分析

第15章 主要7カ国：市場の展望

• 米国：市場規模
• 欧州5カ国：市場規模・展望
• ドイツ
• フランス
• イタリア
• スペイン
• 英国
• 日本市場の展望

第16章 再発/難治性急性骨髄性白血病：アクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightの能力

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Relapsed/Refractory Acute Myeloid Leukemia Epidemiology (2020-2034)
• Table 2: 7MM Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases (2020-2034)
• Table 3: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in the United States (2020-2034)
• Table 4: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Germany (2020-2034)
• Table 6: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in France (2020-2034)
• Table 8: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Italy (2020-2034)
• Table 10: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Spain (2020-2034)
• Table 12: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in the UK (2020-2034)
• Table 14: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Japan (2020-2034)
• Table 16: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Relapsed/Refractory Acute Myeloid Leukemia Epidemiology (2020-2034)
• Figure 2: 7MM Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in the United States (2020-2034)
• Figure 4: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Germany (2020-2034)
• Figure 6: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in France (2020-2034)
• Figure 8: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Italy (2020-2034)
• Figure 10: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Spain (2020-2034)
• Figure 12: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in the UK (2020-2034)
• Figure 14: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Relapsed/Refractory Acute Myeloid Leukemia Epidemiology in Japan (2020-2034)
• Figure 16: Relapsed/Refractory Acute Myeloid Leukemia Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Relapsed/Refractory Acute Myeloid Leukemia - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Relapsed/Refractory Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Relapsed/Refractory Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Relapsed/Refractory Acute Myeloid Leukemia market report provides current treatment practices, emerging drugs, Relapsed/Refractory Acute Myeloid Leukemia market share of the individual therapies, current and forecasted Relapsed/Refractory Acute Myeloid Leukemia market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Relapsed/Refractory Acute Myeloid Leukemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Relapsed/Refractory Acute Myeloid Leukemia Disease Understanding and Treatment Algorithm

The DelveInsight Relapsed/Refractory Acute Myeloid Leukemia market report gives a thorough understanding of the Relapsed/Refractory Acute Myeloid Leukemia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Relapsed/Refractory Acute Myeloid Leukemia.

Treatment

It covers the details of conventional and current medical therapies available in the Relapsed/Refractory Acute Myeloid Leukemia market for the treatment of the condition. It also provides Relapsed/Refractory Acute Myeloid Leukemia treatment algorithms and guidelines in the United States, Europe, and Japan.

Relapsed/Refractory Acute Myeloid Leukemia Epidemiology

The Relapsed/Refractory Acute Myeloid Leukemia epidemiology division provide insights about historical and current Relapsed/Refractory Acute Myeloid Leukemia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Relapsed/Refractory Acute Myeloid Leukemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Relapsed/Refractory Acute Myeloid Leukemia Epidemiology

The epidemiology segment also provides the Relapsed/Refractory Acute Myeloid Leukemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Relapsed/Refractory Acute Myeloid Leukemia Drug Chapters

Drug chapter segment of the Relapsed/Refractory Acute Myeloid Leukemia report encloses the detailed analysis of Relapsed/Refractory Acute Myeloid Leukemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Relapsed/Refractory Acute Myeloid Leukemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Relapsed/Refractory Acute Myeloid Leukemia treatment.

Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Relapsed/Refractory Acute Myeloid Leukemia treatment.

Relapsed/Refractory Acute Myeloid Leukemia Market Outlook

The Relapsed/Refractory Acute Myeloid Leukemia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Relapsed/Refractory Acute Myeloid Leukemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Relapsed/Refractory Acute Myeloid Leukemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Relapsed/Refractory Acute Myeloid Leukemia market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Relapsed/Refractory Acute Myeloid Leukemia market in 7MM.

The United States Market Outlook

This section provides the total Relapsed/Refractory Acute Myeloid Leukemia market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Relapsed/Refractory Acute Myeloid Leukemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Relapsed/Refractory Acute Myeloid Leukemia market size and market size by therapies in Japan is also mentioned.

Relapsed/Refractory Acute Myeloid Leukemia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Relapsed/Refractory Acute Myeloid Leukemia market or expected to get launched in the market during the study period 2020-2034. The analysis covers Relapsed/Refractory Acute Myeloid Leukemia market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Relapsed/Refractory Acute Myeloid Leukemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Relapsed/Refractory Acute Myeloid Leukemia key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Relapsed/Refractory Acute Myeloid Leukemia emerging therapies.

Reimbursement Scenario in Relapsed/Refractory Acute Myeloid Leukemia

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Relapsed/Refractory Acute Myeloid Leukemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Relapsed/Refractory Acute Myeloid Leukemia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Relapsed/Refractory Acute Myeloid Leukemia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Relapsed/Refractory Acute Myeloid Leukemia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Relapsed/Refractory Acute Myeloid Leukemia epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Relapsed/Refractory Acute Myeloid Leukemia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Relapsed/Refractory Acute Myeloid Leukemia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Relapsed/Refractory Acute Myeloid Leukemia market

Report Highlights:

• In the coming years, Relapsed/Refractory Acute Myeloid Leukemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Relapsed/Refractory Acute Myeloid Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Relapsed/Refractory Acute Myeloid Leukemia. Launch of emerging therapies will significantly impact the Relapsed/Refractory Acute Myeloid Leukemia market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Relapsed/Refractory Acute Myeloid Leukemia
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Relapsed/Refractory Acute Myeloid Leukemia Report Insights

• Patient Population
• Therapeutic Approaches
• Relapsed/Refractory Acute Myeloid Leukemia Pipeline Analysis
• Relapsed/Refractory Acute Myeloid Leukemia Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Relapsed/Refractory Acute Myeloid Leukemia Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Relapsed/Refractory Acute Myeloid Leukemia Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Relapsed/Refractory Acute Myeloid Leukemia market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Relapsed/Refractory Acute Myeloid Leukemia total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Relapsed/Refractory Acute Myeloid Leukemia market size during the forecast period (2024-2034)?
• At what CAGR, the Relapsed/Refractory Acute Myeloid Leukemia market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Relapsed/Refractory Acute Myeloid Leukemia market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Relapsed/Refractory Acute Myeloid Leukemia market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Relapsed/Refractory Acute Myeloid Leukemia?
• What is the historical Relapsed/Refractory Acute Myeloid Leukemia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Relapsed/Refractory Acute Myeloid Leukemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Relapsed/Refractory Acute Myeloid Leukemia?
• Out of all 7MM countries, which country would have the highest prevalent population of Relapsed/Refractory Acute Myeloid Leukemia during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Relapsed/Refractory Acute Myeloid Leukemia treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Relapsed/Refractory Acute Myeloid Leukemia in the USA, Europe, and Japan?
• What are the Relapsed/Refractory Acute Myeloid Leukemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Relapsed/Refractory Acute Myeloid Leukemia?
• How many therapies are developed by each company for Relapsed/Refractory Acute Myeloid Leukemia treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Relapsed/Refractory Acute Myeloid Leukemia treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Relapsed/Refractory Acute Myeloid Leukemia therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed/Refractory Acute Myeloid Leukemia and their status?
• What are the key designations that have been granted for the emerging therapies for Relapsed/Refractory Acute Myeloid Leukemia?
• What are the global historical and forecasted market of Relapsed/Refractory Acute Myeloid Leukemia?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Relapsed/Refractory Acute Myeloid Leukemia market
• To understand the future market competition in the Relapsed/Refractory Acute Myeloid Leukemia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Relapsed/Refractory Acute Myeloid Leukemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Relapsed/Refractory Acute Myeloid Leukemia market
• To understand the future market competition in the Relapsed/Refractory Acute Myeloid Leukemia market

Table of Contents

1. Key Insights

2. Executive Summary of Relapsed/Refractory Acute Myeloid Leukemia

3. Competitive Intelligence Analysis for Relapsed/Refractory Acute Myeloid Leukemia

4. Relapsed/Refractory Acute Myeloid Leukemia: Market Overview at a Glance

• 4.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Share (%) Distribution in 2020
• 4.2. Relapsed/Refractory Acute Myeloid Leukemia Total Market Share (%) Distribution in 2034

5. Relapsed/Refractory Acute Myeloid Leukemia: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Relapsed/Refractory Acute Myeloid Leukemia Treatment and Management
• 8.2. Relapsed/Refractory Acute Myeloid Leukemia Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Relapsed/Refractory Acute Myeloid Leukemia Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Relapsed/Refractory Acute Myeloid Leukemia: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size in 7MM
• 13.3. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in the United States
  • 15.1.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in Germany
  • 15.3.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in France
  • 15.4.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in Italy
  • 15.5.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in Spain
  • 15.6.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in the United Kingdom
  • 15.7.2. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Relapsed/Refractory Acute Myeloid Leukemia Total Market Size in Japan
  • 15.8.3. Relapsed/Refractory Acute Myeloid Leukemia Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Relapsed/Refractory Acute Myeloid Leukemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.